Arrowhead Nanobiotechnology Subsidiaries, Calando Pharmaceuticals, Inc. and Insert Therapeutics Inc., Complete Merger
4/24/2008 9:03:46 AM
More...
|
Insert Therapeutics Inc. to Initiate a Multinational Phase II Clinical Trial of Lead Drug Candidate IT-101 in Ovarian Cancer
4/17/2008 10:34:22 AM
More...
|
Arrowhead Research Corporation (ARWR) Streamlines Business Model of Nanobiotech Subs, Calando Pharmaceuticals, Inc. and Insert Therapeutics Inc.
2/28/2008 8:59:19 AM
More...
|
Calando Pharmaceuticals, Inc. and Insert Therapeutics Inc. Appoint Larry Stambaugh as CEO and President
10/31/2007 8:06:54 AM
More...
|
Insert Therapeutics Inc.'s Lead Anti-Cancer Compound is Highlighted in Public Television Documentary
10/9/2007 12:25:59 PM
More...
|
Arrowhead Research Corporation (ARWR) Subsidiary, Insert Therapeutics Inc., Awarded Patent for Cyclosert(TM) Camptothecin, the Company's Lead Oncology Candidate
9/24/2007 10:11:02 AM
More...
|
Arrowhead Research Corporation (ARWR) Subsidiary, Insert Therapeutics Inc., Publishes Interim Phase I Data from Human Clinical Trials for New Cancer Drug
6/1/2007 1:11:32 PM
More...
|
Arrowhead Research Corporation (ARWR) Subsidiary, Insert Therapeutics Inc., to Present at Institutional Investor Conference
5/17/2007 1:02:59 PM
More...
|
Arrowhead Research Corporation (ARWR) Subsidiary, Insert Therapeutics Inc., to Present at NSTI Nanotech 07 Conference
5/17/2007 12:57:22 PM
More...
|
Arrowhead Research Corporation (ARWR) Subsidiaries Insert Therapeutics Inc. & Calando Pharmaceuticals, Inc. Present Data on Cyclosert(TM) Drug Delivery System at American Association for Cancer Research Meeting
4/16/2007 11:56:05 AM
More...
|
|